Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01704079
Other study ID # CTAP101-CL-3002
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 2012
Est. completion date September 2014

Study information

Verified date December 2019
Source OPKO Health, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated


Description:

This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of CTAP101 Capsules administered for 26 weeks to treat SHPT in subjects ≥18 years of age with stage 3 or 4 CKD and vitamin D insufficiency. The study will be conducted at approximately 40 sites within the United States (US). Approximately 550 subjects will be screened to randomize approximately 210 eligible subjects, stratified by CKD stage (approximately 105 subjects in each stage) in a 2:1 ratio to receive either CTAP101 Capsules or matching placebo. An Interactive Voice Response System (IVRS) will provide study treatment group assignments using the computer-generated randomization code provided by the IVRS vendor. Subjects will receive an initial daily dose of 1 capsule (CTAP101 Capsules, 30 µg, or matching placebo) for the first 12 weeks. After l2 weeks (visit 8) and per pre-defined criteria, the dose may be increased in a blinded fashion by the IVRS with oversight by an independent medical monitor.


Recruitment information / eligibility

Status Completed
Enrollment 216
Est. completion date September 2014
Est. primary completion date August 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Urinary albumin excretion = 3000 mcg/mg of creatinine

2. Stage 3 or 4 CKD

3. Plasma iPTH: = 85 pg/mL and < 500 pg/mL

4. Serum Ca: = 8.4 mg/dL and < 9.8 mg/dL

5. Serum P: = 2.0 mg/dL and < 5.0 mg/dL

6. Serum 25-hydroxyvitamin D: = 10 ng/mL and < 30 ng/mL.

7. Stable dose of Vitamin D therapy = 1600 IU/day and receiving same dose for at least 2 months

Exclusion Criteria:

1. History of kidney transplant or parathyroidectomy

2. Spot urine calcium:creatinine ratio > 0.2 (>200 mg/g Cr)

3. Current serious illness, such as malignancy, HIV, liver disease, cardiovascular event or hepatitis

4. Currently on dialysis

5. Use of pharmacological dose of ergocalciferol or cholecalciferol (= 50,000 IU mcg per month) during the study

Study Design


Intervention

Drug:
CTAP101 30 µg capsules
CTAP101 30 µg capsule taken daily at bedtime
Other:
Sugar pill to CTAP101 30 µg capsules
Sugar pill capsule (placebo to CTAP101 30 µg capsule) taken daily at bedtime.

Locations

Country Name City State
United States OPKO Renal Bannockburn Illinois

Sponsors (1)

Lead Sponsor Collaborator
OPKO IP Holdings II, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of =30% From Pre-treatment Baseline Number of subjects in the intent to treat population attaining mean decrease in plasma intact Parathyroid Hormone (iPTH) of =30% from P\pre-treatment baseline in the efficacy assessment phase (EAP) referred to as responders Approximately 6 months
Secondary Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of =30% From Pre-treatment Baseline Number of subjects in the per protocol population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of =30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders Approximately 6 months
Secondary Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D Subjects in the intent to treat population with normal serum total 25-hydroxyvitamin D (>/= 30 ng/dL) Approximately 6 months
Secondary Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D Subjects in the per protocol population with normal serum total 25-hydroxyvitamin D (>/= 30 ng/mL) Approximately 6 months
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4